Geron Presents Positive Results from Phase 2 Study of Imetelstat in Essential Thrombocythemia at the American Society of Hematology Annual Meeting

Geron Presents Positive Results from Phase 2 Study of Imetelstat in Essential Thrombocythemia at the American Society of Hematology Annual Meeting

[at noodls] – MENLO PARK, Calif., December 10, 2012 – Geron Corporation (Nasdaq: GERN) today announced positive clinical results from the Phase 2 trial of imetelstat, the company’s first-in-class telomerase inhibitor, … more

View todays social media effects on GERN

View the latest stocks trending across Twitter. Click to view dashboard

See who Geron is hiring next, click here to view

Share this post

Comments (0)